Abstract
In the present work recent results obtained in the pharmacochemistry of the furoxan system are reported. In particular, after a brief description of the salient points of the furoxan chemistry, the synthesis and the properties of a series of Nifedipine and Prazosin analogues, containing this heterocyclic system, are described. Since we observed that a few furoxan derivatives are able to elicit both a dose-dependent rise in platelet cGMP levels and to promote a dose-dependent inhibition of AA-induced [Ca++] rise, and that many substituted furoxans show potent vasodilating and antiaggregatory activity, the possibility of using the furoxan system as a lead in the design of new vasodilators is also discussed.
MeSH terms
-
Animals
-
Blood Platelets / drug effects
-
Blood Platelets / metabolism
-
Calcium Channel Blockers / pharmacology
-
Cyclic GMP / blood
-
Guinea Pigs
-
Heart Rate / drug effects
-
Humans
-
In Vitro Techniques
-
Myocardial Contraction / drug effects
-
Nifedipine / analogs & derivatives*
-
Nifedipine / chemical synthesis
-
Nifedipine / pharmacology
-
Oxadiazoles / chemistry
-
Oxadiazoles / pharmacology*
-
Platelet Aggregation Inhibitors / chemical synthesis
-
Platelet Aggregation Inhibitors / pharmacology
-
Prazosin / analogs & derivatives*
-
Prazosin / chemical synthesis
-
Prazosin / pharmacology
-
Vasodilator Agents / chemical synthesis
-
Vasodilator Agents / pharmacology
Substances
-
Calcium Channel Blockers
-
Oxadiazoles
-
Platelet Aggregation Inhibitors
-
Vasodilator Agents
-
furoxans
-
Cyclic GMP
-
Nifedipine
-
Prazosin